Source comparison
Melanotan-1 Support Tan Optimization Research: Clinical Evidence Comparison
EPP patients (N=94, NEJM 2015) 16mg controlled-release implant Median pain-free sun exposure time Increased from 6 min baseline to 69 min at peak Melanotan-1 provides measurable photoprotection in severe photosensitivity—most robust clinical evidence to date V
This comparison does not assign a generated winner or score.
- EPP patients (N=94, NEJM 2015)
- 16mg controlled-release implant
- Median pain-free sun exposure time
- Increased from 6 min baseline to 69 min at peak
- Melanotan-1 provides measurable photoprotection in severe photosensitivity—most robust clinical evidence to date
- Vitiligo patients (N=24, Br J Dermatol 2012)
- 0.16mg/kg SC + NB-UVB vs NB-UVB alone
- Percentage achieving ≥50% repigmentation
- 40% combination vs 12% monotherapy at 12 weeks
- MC1R activation accelerates repigmentation when combined with phototherapy but does not replace it
- Healthy volunteers (N=32, JAAD 2006)
- 0.16mg/kg SC for 10 days + controlled UV exposure
- Minimal erythema dose (MED) reduction
- MED increased 2.5-fold vs baseline
- Direct evidence that melanocortin-driven pigmentation reduces UV-induced erythema independent of prior tanning
- Fitzpatrick I–II subjects (N=18, Pigment Cell Res 2004)
- 0.12mg/kg SC × 5 doses
- Cyclobutane pyrimidine dimer formation post-UV
- 47% reduction in CPD levels vs untreated controls
- Melanotan-1 pretreatment reduces DNA damage markers even in individuals with impaired natural melanogenesis